A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis

OBJECTIVE: To demonstrate pharmacokinetic equivalence of CT-P10 and innovator rituximab (RTX) in patients with rheumatoid arthritis (RA) with inadequate responses or intolerances to antitumour necrosis factor agents. METHODS: In this randomised phase I trial, patients with active RA were randomly as...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Dae Hyun, Suh, Chang-Hee, Shim, Seung Cheol, Jeka, Slawomir, Cons-Molina, Francisco Fidencio, Hrycaj, Pawel, Wiland, Piotr, Lee, Eun Young, Medina-Rodriguez, Francisco G, Shesternya, Pavel, Radominski, Sebastiao, Stanislav, Marina, Kovalenko, Volodymyr, Sheen, Dong Hyuk, Myasoutova, Leysan, Lim, Mie Jin, Choe, Jung-Yoon, Lee, Sang Joon, Lee, Sung Young, Kwon, Taek Sang, Park, Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446025/
https://www.ncbi.nlm.nih.gov/pubmed/27624791
http://dx.doi.org/10.1136/annrheumdis-2016-209540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446025/
https://www.ncbi.nlm.nih.gov/pubmed/27624791
http://dx.doi.org/10.1136/annrheumdis-2016-209540

Ejemplares similares